Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncternal Therapeutics Inc (DE:GTU2)
FRANKFURT:GTU2
RESEARCH TOOLSreports
Oncternal Therapeutics (GTU2) Stock Price & Analysis
0 Followers
GTU2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.04 - €23.43
Previous Close€5.32
Volume0.00
Average Volume (3M)1.01K
Market Cap
€19.49M
Enterprise Value-€17.06M
Total Cash (Recent Filing)$40.30M
Total Debt (Recent Filing)$342.00K
Price to Earnings (P/E)N/A
Beta1.04
Next Earnings
Mar 07, 2024EPS Estimate
-€2.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,968,902
10 Day Avg. Volume0
30 Day Avg. Volume1,012
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.66
Price to Sales (P/S)12.59
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-25.89
Enterprise Value/Gross Profit-11.45
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
€41.05Price Target Upside671.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Oncternal Therapeutics News
GTU2 FAQ
What was Oncternal Therapeutics Inc’s price range in the past 12 months?
Oncternal Therapeutics Inc lowest stock price was €4.04 and its highest was €23.43 in the past 12 months.
What is Oncternal Therapeutics Inc’s market cap?
Currently, no data Available
When is Oncternal Therapeutics Inc’s upcoming earnings report date?
Oncternal Therapeutics Inc’s upcoming earnings report date is Mar 07, 2024 which is 49 days ago.
How were Oncternal Therapeutics Inc’s earnings last quarter?
Oncternal Therapeutics Inc released its earnings results on Nov 09, 2023. The company reported -€3.102 earnings per share for the quarter, missing the consensus estimate of -€2.646 by -€0.456.
Is Oncternal Therapeutics Inc overvalued?
According to Wall Street analysts Oncternal Therapeutics Inc’s price is currently Undervalued.
Does Oncternal Therapeutics Inc pay dividends?
Oncternal Therapeutics Inc does not currently pay dividends.
What is Oncternal Therapeutics Inc’s EPS estimate?
Oncternal Therapeutics Inc’s EPS estimate is -€2.8.
How many shares outstanding does Oncternal Therapeutics Inc have?
Currently, no data Available
What happened to Oncternal Therapeutics Inc’s price movement after its last earnings report?
Oncternal Therapeutics Inc reported an EPS of -€3.102 in its last earnings report, missing expectations of -€2.646. Following the earnings report the stock price went up 13.675%.
Which hedge fund is a major shareholder of Oncternal Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:GTU2
---
Oncternal Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€41.05 (671.66% Upside)
€41.05 (671.66% Upside)
Blogger Sentiment
Bullish
DE:GTU2 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-65.86%
12-Months-Change
Fundamentals
Return on Equity
-79.05%
Trailing 12-Months
Asset Growth
-43.29%
Trailing 12-Months
Company Description
Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focus is on drug development on promising yet untapped biological pathways implicated in cancer progression. The company was founded in 1997 and is headquartered in San Diego, CA.
---
GTU2 Earnings Call
Q3 2023
0:00 / 0:00
---
GTU2 Stock 12 Months Forecast
Average Price Target
€41.05
▲(671.66% Upside)
Technical Analysis
Oncternal Therapeutics
―
Arcutis Biotherapeutics
―
RegenXBio
―
MacroGenics
―
Arcturus Therapeutics
―
Best Analysts Covering GTU2
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-47.52%
reiterated a buy rating 4 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -47.52% per trade.
---